The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Non-Small Cell Lung Cancer
Advertisement
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
Nicolas Girard, MD, PhD, of Institut Curie, presented the findings from expansion cohorts of the study at ELCC 2025.
Xiuning Le, MD, PhD, presented results from the ORCHARD trial at ELCC 2025.
The award recognizes his "exceptional contributions to thoracic oncology research and education."
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The multicenter, single-arm trial is evaluating the novel antibody–drug conjugate, also known as SHR-A1811.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Dr. Liu unpacks key questions in the field, and the research that could address them.
Certain surgical procedures and margins were more frequent in patients who had suture-line recurrences.
The long-term follow-up data shows that PFS remains unreached in the subgroup of Asian patients in the CROWN study.
Advertisement
Expert Interviews
Advertisement
Section Editor
Stephen V. Liu, MDThoracic Medical Oncologist | Georgetown University
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.